Ignite Creation Date:
2024-05-05 @ 11:44 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00110448
Status:
COMPLETED
Last Update Posted:
2016-11-02
First Post:
2005-05-09
Brief Title:
Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes JPAD Trial
Sponsor:
Kumamoto University
Organization:
Kumamoto University
Study Overview
Official Title:
Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes JPAD Trial
Status:
COMPLETED
Status Verified Date:
2008-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the effects of low-dose aspirin for the primary prevention of vascular events in patients with type 2 diabetes in Japan
Detailed Description:
There is a worldwide epidemic of diabetes and the number of individuals with diabetes is set to increase further As individuals with diabetes are at high risk of accelerated atherosclerosis and thrombotic vascular events the significant proportion of the cardiovascular disease burden is projected to be among this population JPAD is a multicenter study with a prospective randomized open blinded end-point PROBE design The doses administered are aspirin 81 mgday or 100 mgday the latter being enteric-coated Aspirin
The primary objective was to compare the effect of aspirin on atherosclerotic events including cardiovascular events cerebral vascular event and other vascular events
We also analyze hemorrhagic events in this RCT
The primary objective was to compare the effect of aspirin on atherosclerotic events including cardiovascular events cerebral vascular event and other vascular events
We also analyze hemorrhagic events in this RCT
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None